Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anand Veerapathran"'
Autor:
David McDermott, Virginia Seery, Rupal Bhatt, Adrian Wells, Mamta Gupta, Brian Halbert, David Einstein, Emanuelle Andrianopoulos, Kenneth Onimus, Courtney Herman, Shwetha Lakshmipathi, Arvind Natarajan, Anand Veerapathran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ac294b04595448f389f6a445c691e5f3
Autor:
Arvind Natarajan, Anand Veerapathran, Adrian Wells, Kenneth Onimus, Marcus Machin, Seth Wardell, Jamie L. Blauvelt, Madan Jagasia, Rafael Cubas
Publikováno v:
Cancer Research. 82:2746-2746
Background: Adoptive cell therapy with autologous TIL has demonstrated an objective response rate (ORR) of 36% in the post-immune checkpoint inhibitor (ICI) setting in patients (pts) with advanced/unresectable melanoma (Sarnaik JCO 2021), while in IC
Autor:
Adrian Wells, Arvind Natarajan, Anand Veerapathran, Shwetha Lakshmipathi, Courtney Herman, Joe Wypych, Viktoria Gontcharova, Nermin Gerges, Kenneth Onimus
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A110-A110
BackgroundLifileucel (LN-144) and LN-145, adoptive cell therapies using autologous tumor-infiltrating lymphocytes (TIL), have demonstrated encouraging efficacy with acceptable safety in a variety of tumor types.1–4 The lifileucel Gen 2 clinical man
Autor:
Brian Halbert, David Einstein, David McDermott, Emanuelle Andrianopoulos, Mamta Gupta, Virginia Seery, Kenneth Onimus, Courtney Herman, Adrian Wells, Shwetha Lakshmipathi, Arvind Natarajan, Anand Veerapathran, Rupal Bhatt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPatients with RCC may achieve remission with immune-checkpoint inhibitors (ICI); however, most patients will progress. Adoptive cell therapy with autologous TIL allows for expansion of T-cells from tumor tissue leading to a polyclonal T-cel
Autor:
Amit A. Lugade, Cecile Chartier, Elizabeth Brese, Adrian Wells, Maria Fardis, Anand Veerapathran, Arvind Natarajan, Gurkamal Chatta, Kunle Odunsi, Qiang J. Li, Khurshid A. Guru, Kenneth Onimus
Publikováno v:
Clinical Cancer Research. 26:A05-A05
Background: Patients with advanced bladder cancer have limited therapeutic options, apart from cisplatin-based chemotherapy and use of immune checkpoint inhibitors (ICI). Median survival for patients with metastatic disease is 15 to 18 months. Hence
Autor:
Krit Ritthipichai, Marcus Machin, Michelle Simpson-Abelson, Christopher Mosychuk, Anand Veerapathran, Michael Lotze
Publikováno v:
The Journal of Immunology. 198:198.1-198.1
Only two K+ channels are known to be expressed by T-cells. Activated effector T cells express high levels of Kv1.3; activated naïve and central memory T-cell subsets express high levels of KCa3.1. Overexpression of Kv1.3 in murine T-cells increases
Autor:
Einstein, David J., Halbert, Brian, Denize, Thomas, Matar, Sayed, West, Destiny J., Gupta, Mamta, Andrianopoulos, Emanuelle, Seery, Virginia, Herman, Courtney, Onimus, Kenneth, Wells, Adrian, Bunch, Brittany, Signoretti, Sabina, Natarajan, Arvind, Veerapathran, Anand, McDermott, David F.
Publikováno v:
Journal of Immunotherapy; Nov/Dec2024, Vol. 47 Issue 9, p361-368, 8p
Publikováno v:
Immunotherapy Weekly; 11/5/2024, p843-843, 1p